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Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family
proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis
of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor
prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy
to kill the myeloma cells. Over the last decade, the development of selective Mcl-1
inhibitors has seen remarkable advancement. This review presents the critical role of
Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic
that selectively inhibit Mcl-1, and could be used as single agent or combined with existing
therapies.
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INTRODUCTION
The innate and adaptive immune system comprises several different types of cells that elegantly work
together to stave off infection and remove transformed or damaged cells. Lymphocytes including
both T- and B-cells are among the most important cellular category within the immune system. The
plasma cells are a type of unique B cells that reside in the bone marrow (BM) and secrete an antibody
corresponding to the antigen. When these plasma cells begin proliferating out of control, they can
build up within the BM and form numerous tumors across the body (Figure 1). This type of
neoplasms is called Multiple Myeloma (MM) and considered the second most common hematologic
malignancy, accounting around 12% of hematological malignancies (Kazandjian, 2016). MM is
slightly more common among older men, with the median age of 65 years, and it is rarely diagnosed
in younger people (Kumar et al., 2008; Gerecke et al., 2016; Naymagon and Abdul-Hay, 2016).
Depending on the stage of disease, symptoms of MM begin with abnormalities in the bone and
calcium homeostasis, low blood cell counts, renal insufficiency, and multiple infections. Because the
symptoms are so generalized, MM is a challenging disease to diagnose. Furthermore, the protective
role of the BM on the proliferating plasma cells make it even more challenging to treat.
In the last several decades the treatment options for MM have dramatically improved,
unfortunately, the survival rate is marginal (Bergsagel and Kuehl, 2005). According to the
American Cancer Society 2021 estimation, approximately 34,920 new MM cases will be
diagnosed (19,320 men and 15,600 women), approximately 12,410 cancer deaths (6,840 men
and 5,570 women) from MM alone in the United States (Siegel et al., 2021). Table 1 illustrates
the common drugs that have been used to treat MM patients. Most therapeutic approaches to date
for MM patients, especially in relapsed/refractory (R/R) cases have been based on combined
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formulations of available therapies. In spite of the efficacy and
diversity of therapeutic approaches, drug resistance is a major
challenge as MM continues to show high rates of relapse and
quickly acquired resistance to therapies (Abdi et al., 2013). There
are several unanswered questions regarding MM including: what
are the causes of progression of MM from its precursor state?
Why MM patients instigate to relapse? How MM clones resistant
to drugs persist in the presence of effective therapies?
MCL-1 PROTEIN AS A POTENTIAL TARGET
FOR MULTIPLE MYELOMA
Apoptosis is a vital procedure for regular development and
maintaining the tissue homeostasis. Mammalian apoptosis
occurs via one of two distinct pathways, either the intrinsic or
extrinsic pathways (Figure 2). Both the intrinsic and extrinsic
pathways end with the activation of a certain group of protease
enzymes called Caspase proteins. The intrinsic pathway entails
mitochondrial outer membrane permeabilization (MOMP) that
regulates directly by interactions between B cell lymphoma 2
(Bcl-2) family proteins. The Bcl-2 family proteins are critical
regulators of apoptosis. The members of this family proteins are
divided into three groups according to function: anti-apoptotic
proteins (Bcl-2, Mcl-1, Bcl-xL, Bcl-W, and Bfl-1); pro-apoptotic
BH3-only proteins (Noxa, Puma, Bim, Bid, Bad, BMF, and Bik);
and multi-domain pro-apoptotic proteins (Bax, Bak, and Bok).
Intrinsic pathways like cytokine deprivation or DNA damage
promote overexpression and activation of BH3-only proteins,
which stimulate apoptosis in two different ways. First, the BH3-
only proteins behave as inhibitors of anti-apoptotic proteins by
competing for their binding with Bax and Bak proteins (Czabotar
et al., 2014; Figure 2). This is accomplished via the amphipathic
α-helix of the BH3 domain that contains four hydrophobic
residues (h1-h4) that bind four hydrophobic pockets (P1−P4)
within the anti-apoptotic proteins in their BH3 binding groove
(Liang and Fesik, 1997; Czabotar et al., 2007; Stewart et al., 2010).
For example, Noxa selectively inhibits Mcl-1 with high affinity
binding thereby indirectly activating the Bax/Bak pathway (Smith
et al., 2011; Kale et al., 2018). Simultaneously, BH3-only proteins
can also result in the direct activation of multi-domain pro-
apoptotic proteins Bax and Bak, which cause MOMP, leading to
release of Cytochrome C and SMAC proteins into the cytosol
resulting in downstream Caspase activation and ultimately
activation of apoptosis (Dewson and Kluck, 2009).
The extrinsic pathway is promoted by death receptors
activation. This leads to activation of initiator Caspases 8 and
10, which can directly induce the downstream executioner
Caspase such as Caspase 3 and 7 to drive full commitment to
apoptosis (Kaufmann et al., 2012). Moreover, Caspases 8 and
Caspase 10 can activate Bid, which in turn activates Bak and Bax
to induce MOMP, which is the connecting link between the
extrinsic and intrinsic pathways (Kaufmann et al., 2012;
Figure 2).
FIGURE 1 |Multiple myeloma (MM). MM is a type of blood cancer that initiates from the bone marrow (BM), arising from the aberrant proliferation of plasma cells.
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The mitochondrial membrane engages Mcl-1 with other Bcl-2
family partners for initiation of apoptosis. The interaction
between the family members determine the outcome (Kale
et al., 2018). Mcl-1 has a diverse localization within human
cells. It is primarily found within the mitochondrial outer and
inner membranes (Yang et al., 1995). However, studies have
reported its localization in the nucleus and cytoplasm of
polymorphonuclear leukocytes (PMNs) (Leuenroth et al.,
2000). How different localization affects the function and its
stability is not known.
The studies of Kozopas et al. first proved a high Mcl-1
expression in a differentiating human myeloid leukemia ML-1
cell line (Kozopas et al., 1993). Subsequently, it was shown to be
expressed in several different cells as well. The MM cells exhibit
imbalances in their anti-apoptotic proteins expression levels,
especially Mcl-1 that leads to defects in the mitochondrial
intrinsic pathway (Derenne et al., 2002; Zhang et al., 2002). In
order to prevent apoptosis and allow continued cell growth, Mcl-
1 forms a heterodimer protein-protein interaction with multi-
domain pro-apoptotic proteins Bax and Bak (Sedlak et al., 1995;
Willis and et al., 2005). Mcl-1 is known to be highly expressed in
MM cells and plays a pivotal role in MM initiation, progression,
and apoptosis resistance (Derenne et al., 2002; Zhang et al., 2002).
Newly diagnosed cases of MM have continued to show increasing
Mcl-1 protein expression, which predicts a higher relapse and
poor patient survival rate (Wuillème-Toumi et al., 2005). Thus,
Mcl-1 is an attractive therapeutic target for MM.
REGULATION OF MCL-1 PROTEIN
The interaction of myeloma cells to BM microenvironment
(BMM) is the hall mark of MM (Figure 3). Additionally, MM
cells receive crucial signals from the BMM that help them to
evade apoptosis in order to maintain their long-term survival.
The BM stromal cells (BMSCs) regulate the anti-apoptotic Bcl-2
family proteins by secreting a group of signaling cues. Mcl-1 is
regulated through several extracellular signaling molecules
including interleukins (IL-3, IL-5, and IL-6) (Wang et al.,
1999; Huang et al., 2000; Jourdan et al., 2000); growth factors
such as vascular endothelial growth factor (VEGF), epidermal
growth factor (EGF) (Leu et al., 2000; Le Gouill et al., 2004);
granulocyte macrophage colony stimulating factors (GM-CSF)
(Chao et al., 1998); and interferon alpha (INF-α) (Jourdan et al.,
2000). Combined, these stimuli trigger and modulate multiple
signaling pathways including Janus kinase/signal transducer and
activator of transcription (JAK/STAT), rat sarcoma/mitogen-
activated protein kinase (Ras/MAPK), MEK/extracellular
signal-related kinase (ERK) as well as phosphatidylinositol-3
kinase (PI3-K)/Akt (Figure 3).
The cytokine IL-6 is a main survival factor for MM cells (Klein
et al., 1995). IL-6 triggers the upregulation of Mcl-1, Bcl-xL, and
VEGF via stimulation of the JAK/STAT-3 signaling pathway
(Puthier et al., 1999; Dankbar et al., 2000). In turn, VEGF
promotes IL-6 induction in neighboring BM cells (BMCs)
(Dankbar et al., 2000). Furthermore, IL-6 induces survival of
TABLE 1 | Mechanism of action and Side effects of Common Therapy in MM.
Drug Mechanism of action Side effects Ref
Melphalan Chemotherapy drug Bone marrow damage and chemotherapy side effects Bergsagel et al. (1962)
Thalidomide
(Thalomid)
Immunomodulating agent Drowsiness, fatigue, constipation, and painful nerve damage as well
as severe birth defects when taken during pregnancy
Singhal et al. (1999)
Bortezomib
(Velcade)
Proteasome inhibitor Vomiting, tiredness, diarrhea, constipation, decreased appetite,
fever, lowered blood counts and nerve damage
Richardson et al. (2003)
Lenalidomide
(Revlimid)
Small molecule analogue of
thalidomide
Drowsiness, fatigue, constipation, and painful nerve damage as well
as severe birth defects when taken during pregnancy
Hideshima et al. (2000), Rajkumar et al.
(2005), Richardson et al. (2002)
Carfilzomib
(Kyprolis)
Proteasome inhibitor Tiredness, nausea, vomiting, diarrhea, shortness of breath, fever and
low blood counts and occasionally more serious problems such as
pneumonia, heart problems, and kidney or liver failure
Herndon et al. (2013)
Pomalidomide
(Pomalyst)
Small molecule analogue of
thalidomide
Same thalidomide side effects with a less risk of nerve damage side
effect





Feeling tired, weakness, nausea, diarrhea vomiting, loss of appetite,
fever, swelling in the arms or legs, and occasionally altered blood cell
counts and blood electrolytes. Rare cases of internal bleeding, liver
damage, and changes in heart rhythm which can sometimes be life
threatening
Laubach et al. (2015)
Ixazomib (Ninlaro) Oral proteasome inhibitor Nausea, vomiting, diarrhea, constipation, swelling in the hands or
feet, back pain, lowered blood platelet count and nerve damage





Coughing, wheezing, trouble breathing, throat tightness, runny nose,
nasal congestion, feeling dizzy or lightheaded, headache, rash,
nausea, fatigue, back pain, fever, and lower blood cell counts





Chills, feeling dizzy or lightheaded, wheezing, trouble breathing,
cough, tightness in the throat, runny nose, nasal congestion, upper
respiratory tract infections and pneumonia, rash, fatigue, loss of
appetite, diarrhea, constipation, fever, and nerve damage
Lonial et al. (2015)
Selinexor (Xpovio) Oral Nuclear export inhibitor of
XPO1
Diarrhea, nausea, vomiting, loss of appetite, weight loss, low blood
sodium levels susceptibility to infection, low platelet counts, and low
white blood cell counts
Vogl et al. (2018)
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MM cells via stimulating the Ras/MAPK pathway, which engage
in Mcl-1 overexpression (Ogata et al., 1997). Additionally, IFN-α
induces Mcl-1 in a STAT-3 dependent manner (Jourdan et al.,
2000). Furthermore, the tumor necrosis factor (TNF) family
including B cell activating factor (BAFF), a proliferation-
inducing ligand (APRIL) prevent apoptosis by inducing the
expression of Mcl-1 and Bcl-2 (Moreaux et al., 2004). Insulin
like growth factor 1 (IGF-1) affects the cell survival, by
downregulating pro-apoptotic protein Bim (De Bruyne et al.,
2010). The imbalance between Bim and Mcl-1 expression plays
an important role in MM cell survival (Gomez-Bougie et al.,
2004). The transcription factors such as B lymphocyte induced
maturation protein 1 (Blimp-1), X-box binding protein 1 (XBP-
1), and interferon regulatory factor 4 (IRF4) are critical for
myeloma cells differentiation and development (Calame et al.,
2003). The Blimp-1 downregulates the expression of pro-
apoptotic protein Bim (Lin et al., 2007).
Mcl-1 and other anti-apoptotic proteins contain four Bcl-2
homology (BH) domains (BH1-3 domains interact to form a
hydrophobic cleft termed “BH3-binding groove”), and a
C-terminal tail of hydrophobic transmembrane domain (TM)
that permeates into the mitochondrial membrane (Kozopas et al.,
1993). Interestingly, compared to the other anti-apoptotic
proteins, Mcl-1 has several unique properties including unique
binding site, size, half-life, and localization. Mcl-1 has a shallow,
relatively inflexible and more electropositive binding site
abundant in lysine and histidine residues (Denis et al., 2020).
Bcl-2 and Bcl-xL proteins contain 233 amino acids, whereas Mcl-
1 protein contains 350 amino acids. This size difference is due to
the presence of a large N-terminal domain of four PEST
sequences [amino acids sequence extensive in proline (P),
glutamic acid (E), serine (S), and threonine (T)] (Kozopas
et al., 1993; Thomas et al., 2010), which can target Mcl-1 for
degradation through the ubiquitin-proteasome system (UPS) and
renders it short half-life (usually less than three hours depending
on the cellular conditions) (Rogers et al., 1986; Kozopas et al.,
1993; Yang et al., 1995).
In MM, the Mcl-1 gene is the most important and selective of
the survival genes (Tiedemann et al., 2012). Gene coding of Mcl-1
is located on chromosome 1q21 region. Approximately 40% of
MM cases have shown chromosomal amplification of 1q21, hence
increased Mcl-1 expression (Shah et al., 2018; Slomp et al., 2019).
Additionally, the gene coding of cytokine interleukin 6 receptor
(IL-6R) is located on the same chromosome region (1q21)
(Pawlyn and Morgan, 2017). The coding region of Mcl-1
contains three exons and two introns that undergoes
alternative splicing to produce mature RNA (mRNA)
isoforms. The Mcl-1L (Mcl-1 long) splice variant joins the
three exons, has a full length of 350 amino acids and acts as
an anti-apoptotic. On the other hand, Mcl-1S (Mcl-1 short) joins
FIGURE 2 | The programmed cell death- via intrinsic and extrinsic pathways in normal mammalian cells. Intrinsic and extrinsic pathways result in the activation of a
family of protease enzymes called Caspase proteins. The intrinsic pathway is promoted by cellular stresses that modulate Bcl-2 family proteins and activates Bak and
Bax. In the indirect activation, upregulation of BH3-only proteins will act as inhibitors of anti-apoptotic proteins by competing for their binding with Bax and Bak proteins,
leading Bax and Bak to oligomerize. In the direct activation, upregulation of BH3 activators proteins directly activates Bax and Bak. This activation leads to
mitochondrial outer membrane permeabilization (MOMP), subsequently Cytochrome C and SMAC proteins release into the cytosol, causing the downstream of
Caspase activation that ends with apoptosis. The extrinsic pathway is promoted by death receptors activation. This leads to activation of initiator Caspases 8 and 10,
which can regulate the downstream executioner Caspase such as Caspase 3 and 7 to drive full commitment to apoptosis. Moreover, Caspases 8 and 10 can activate
Bid, which in turn activates Bak and Bax to induce MOMP which establishes the link between the extrinsic and intrinsic pathways.
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only the first and the third exons without the central exon, with
length of 271 amino acids, shows increased cytosolic localization
and lacks the BH1, BH2 and TM domains but has the BH3
domain which plays a critical pro-apoptotic role (Bae et al., 2000;
Bingle et al., 2000). Interestingly, Kim et al. (2009), found a new
alternative splicing variant detected in the mitochondrion termed
Mcl-1ES (Mcl-1 extra short) with a shorter length of 197 amino
acids due to an absence of PEST sequences (Kim et al., 2009).
Mcl-1ES forms an interaction with Mcl-1L in order to induce
apoptosis (Kim et al., 2009).
The post transcriptional regulation of Mcl-1 is complex and
controlled by multiple RNA binding proteins (RPBs) and
microRNAs (miRNAs). For example, Mcl-1 has been shown to
be downregulated in MM by miR-29b, miR-137, and miR-197
that leads to apoptosis (Zhang et al., 2011; Yang et al., 2015; Cui
and Placzek, 2018). Additionally, at the post-translational level,
the large N-terminal domain PEST allows for non-proteasomal
degradation via cleavage (Herrant et al., 2004), proteasomal
degradation via phosphorylation (Thomas et al., 2010), and
ubiquitination (Mojsa et al., 2014), which further impact Mcl-
1 expression, stability, localization, and function. Mcl-1 PEST
undergoes Caspase cleavage at two different sites, located at
Asp127 that produce Mcl-11–127 associated with Mcl-1128–350.
At Asp158 that produce Mcl-11–157 associated with Mcl-1158–350
(Herrant et al., 2004). Interestingly, not all Mcl-1 cleavage
fragments revoke anti-apoptotic function. Mcl-1Δ127 fragment
has anti-apoptotic function same as Mcl-1 and exists mainly in
the cytoplasm and sequester BH3-only or Bak in order to prevent
apoptosis (Wang and et al., 2020).
The Mcl-1 phosphorylation plays a critical role in controlling
Mcl-1 function as well. Mcl-1 phosphorylation occurs by several
protein kinases including; c-Jun N-terminal kinase (JNK)
(Inoshita et al., 2002), glycogen synthase kinase 3 (GSK-3)
(Maurer et al., 2006; Ding et al., 2007), and extracellular
signal-regulated kinase (ERK-1) (Domina et al., 2004; Ding
et al., 2008). The phosphorylated Mcl-1 proteins have been
reported to result in different functions according to
phosphorylation sites (Thomas et al., 2010; Senichkin et al.,
2020). Furthermore, a reversible form of post-translational
ubiquitination controls several aspects of Mcl-1 including
stability and proteasomal degradation and allow for rapid
respond to environmental signals in order to change cell state
from survival to apoptosis. The Mcl-1 ubiquitin-proteasome
system is mediated by five different E3 ubiquitin-ligases
including Mcl-1 ubiquitin ligase E3 (Mule) (Zhong et al.,
2005), SCF beta-transducin repeats containing protein
(SCFβ−TrCP) (Ding et al., 2007), SCF F-box and WD repeat
domain containing 7 (SCFFbw7) (Inuzuka et al., 2011),
FIGURE 3 | Bone marrow microenvironment (BMM) in MM. BMM facilitates the long term survival of MM. Stromal cells in BM regulate anti-apoptotic proteins by
secreting a variety of signaling molecules including IL-6 and IFN-α that trigger JAK/STAT pathway, leading to the upregulation of Mcl-1, Bcl-xL, and VEGF. VEGF
promotes IL-6 induction in neighboring BMCs. Furthermore, IL-6 induces survival of MM cells via Ras/MAPK pathway, which modulates the expression of Mcl-1 The
tumor necrosis factor (TNF) family including BAFF and APRIL are other stimuli from the BMM that induce expression of both Mcl-1 and Bcl-2 via tumor necrosis
factor receptor-associated factors (TRAFs) including BAFF-R, BCMA, and TACI. IGF-1 is another stimulus that acts by downregulating Bim, leading to releaseMcl-1. MM
cases have shown chromosomal amplification of 1q21 region, where the gene coding for Mcl-1 and IL-6R are located.
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anaphase-promoting complex/cyclosome (APC/CCdc20) (Harley
et al., 2010), and tripartite motif containing 17 (Trim17) (Magiera
et al., 2013). Furthermore, the ubiquitin-proteasome system
contains an additional deubiquitinase called ubiquitin specific
peptidase 9, X-linked (USP9X) that removes poly-ubiquitin
chains leading to stabilize Mcl-1 and prevent apoptosis
(Schwickart et al., 2010). The degree of ubiquitination is also
subject to variation based upon the variable phosphorylation of
residues of Mcl-1 (Maurer et al., 2006; Ding et al., 2007). Our
understanding of Mcl-1 regulations has been greatly expanded by
the findings that have developed over the years and provide deep
critical insights into exactly how Mcl-1 protein plays such a key
role in cellular apoptosis as well as how it can be modulated to
provide new options of potential therapeutic approach in MM
and other Mcl-1 dependent cancers.
DEVELOPMENT OF SELECTIVE MCL-1
INHIBITORS
Studies have demonstrated that MM depends on Mcl-1 proteins
for survival, prognosis, and chemo resistance. Thus, inhibition of
Mcl-1 offers an attractive target and a promising strategy for
myeloma treatment. Nonetheless, the targeting of Mcl-1 has been
challenging because of its complex regulation. So far, two
approaches have been adopted to inhibit Mcl-1, one is direct
inhibition and second is indirect targeting. The indirect targeting
is a less selective method inhibits other anti-apoptotic proteins,
may have more serious side effects. Whereas, direct Mcl-1
inhibitors target the hydrophobic cleft BH3-binding groove of
BH3-only proteins interactions domain. Therefore, these
inhibitors are very specific to Mcl-1. Here we will review BH3-
mimetic inhibitors that selectively bind Mcl-1. The
structure of these inhibitors are shown in Figure 4. The
current status of development of these agents are
summarized in Table 2.
Indole-2-Carboxylic Acids Analog
(A-1210477)
This was developed by AbbVie in 2008. A-1210477 induces
intrinsic apoptosis pathway by selectively inhibiting Mcl-1
with high binding affinity (Ki  0.454 nM) (Leverson and
et al., 2015). Upon binding, BH3 mimetic A-1210477 results
in an accumulation of Mcl-1 protein by preventing its
degradation. A-1210477 disrupts the Mcl-1:Bim and Mcl-1:
Noxa complexes in order to induce Bax/Bak- dependent
MOMP, leading to Cytochrome C release and Caspase
activation (Leverson and et al., 2015). The treatment of A-
1210477 decreased the association of Mcl-1: Bak complex
within an hour, however the complex was totally disrupted
after three hours of treatment (Gomez-Bougie et al., 2018).
Interestingly, the studies of Mallick et al. (2019) showed that
A-1210477 induces rapid apoptosis within 0.5–1 h of treatment,
without inducing Noxa (Mallick and et al., 2019). A-1210477 as a
monotherapy or in a combination with Navitoclax resulted in
death of different cell lines including MM, melanoma, and non-
small cell lung cancer cell lines that were found to be Mcl-1
dependent by BH3 profiling or siRNA rescue experiments
(Leverson and et al., 2015; Mukherjee and et al., 2018). This
finding was reinforced by the efficacy of A-1210477 as a
combination with Venetoclax against acute myeloid leukemia
(AML) (Fiskus and et al., 2019). A-1210477 inhibited triple
negative breast cancer cell line growth activity in vitro which
FIGURE 4 | Chemical structures of selective Mcl-1 inhibitors. The most prominent Mcl-1 inhibitors including A-1210477, Maritoclax, MIM1, UMI-77, S63845,
S64315/MIK666, AMG-176, AZD5991, and VU661013.
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is also considered a Mcl-1 dependent cells type (Campbell and
et al., 2018). However, a reference showing A-1210477 induced
apoptosis in Bcl-2 dependent cells at higher concentration when
compared withMcl-1 inhibition concentration (Koss et al., 2016).
Unfortunately, no in vivo activity was associated with A-1210477,
even with the most sensitive cell lines. This was attributed to cell
penetration issues and reduced bioavailability due to the high
levels of serum protein binding.
Marinopyrrole A (Maritoclax)
This natural agent was first discovered by Hong-Gang Wangʼs
group at Pennsylvania State University in 2012 (Doi et al., 2012).
The BH3 mimetic drug Maritoclax induces degradation of Mcl-
1 proteins and disrupt Mcl-1: Bim complex. Maritoclax
effectively binds the site of the BH3-only proteins p4 binding
site and leads to apoptosis. Further, it has been reported that this
natural agent is effective against Mcl-1 overexpressing cancer
cells (Doi et al., 2012). Blocking BH3 binding site is related with
increasing amount of Mcl-1 protein, followed by its
ubiquitination and degradation by the E3 ligase (ubiquitin
ligase) (Kaleigh and Manabu, 2013). Moreover, the treatment
of Maritoclax did not result in Noxa upregulation (Doi et al.,
2012). We found that Maritoclax potentiates the apoptotic
response of ABT-737 in human melanoma cells (Pandey and
et al., 2013).
Mcl-1 Inhibitor Molecule 1 (MIM1)
Developed in 2012 by Cohen and co-workers, polyphenol
compound MIM1 acts as a semi BH3 mimetic which induces
Noxa (Cohen et al., 2012). MIM1 seems very similar to BH3
mimetic Mcl-1 inhibitors (Mallick and et al., 2019). This Mcl-1
inhibitor exhibited an ability to induce apoptosis in Mcl-1
dependent cells through upregulation of proapoptotic protein
Noxa, which selectively inhibits Mcl-1 with high affinity binding
(Smith et al., 2011; Kale et al., 2018; Mallick and et al., 2019). Also,
induction of Noxa dissociates Mcl-1:Bim association complex.
Unfortunately, MIM1 was only able to induce Bak dependent
apoptosis at high concentrations (more than 10 μM). MIM1
failed to induce apoptosis in anti-apoptotic proteins dependent
cell lines (Varadarajan et al., 2013).
UMI-77
Developed in 2013 by Zaneta Nikolovska-Coleskaʼs group at
University of Michigan, naphthol derivative UMI-77 is
another semi BH3 mimetic Mcl-1 inhibitor with high binding
affinity (Ki  490 nM) (Azmi and et al., 2013; Abulwerdi et al.,
2014). In order to induce apoptosis, UMI-77 was found to
upregulate pro-apoptotic protein Noxa thereby selectively
inhibit Mcl-1 (Mallick and et al., 2019). UMI-77 and Noxa
competing for Mcl-1 binding with Bax and Bak proteins
ultimately disrupt the Mcl-1: Bak and Mcl-1: Bak complexes,
which results in Cytochrome C release and Caspase 3 activation
(Abulwerdi et al., 2014). The in vitro and in vivo preclinical
studies demonstrated that UMI-77 potently inhibits tumor
growth and induces apoptosis in MM cells (Azmi and et al.,
2013), and pancreatic cancer cells lines (Abulwerdi et al., 2014),
both of which rely on the Mcl-1 protein as a survival factor
(Miyamoto et al., 1999; Schniewind et al., 2004; Ren et al., 2009).
TABLE 2 | Direct Mcl-1 Inhibitors BH3 Mimetic and semi BH3 Mimetic drugs.
Mcl-1
inhibitor
Company Affinity Clinical trial status
A-1210477 Abbive Ki  0.45 nM Preclinical
Maritoclax Hong-GangWang’s group at Pennsylvania
State University
IC50 10 μM Preclinical
MIM1 Cohen and coworkers Only at very high
concentration
Failed in vivo
UMI-77 Zaneta Nikolovska-Coleska’s group at
University of Michigan
Ki  490 nM Preclinical
S63845 Servier and Vernalis Kd  0.19 nM Preclinical
S64315/
MIK666
Servier and Vernalis and Novartis undisclosed Phase I by Novartis, in R/R lymphoma or R/R MM patients (NCT02992483)
Phase I by Servier, in AML and MDS patients (NCT02979366)
Phase I by Servier as a combination of S64315/MIK666 plus Venetoclax in AML
patients (NCT03672695)
AMG-176 Amgen Ki  0.06 nM Phase I in R/R MM and R/R AML patients (NCT02675452)
Phase I as a combination of AMG-176 plus Venetoclax in different R/R
hematologic malignancies including AML, NHL, and DLBCL (NCT03797261)
AMG-397 Amgen undisclosed Phase I clinical trial is evaluating the safety, tolerability, pharmacokinetics, and
efficacy of AMG 397 in MM, AML, DLBCL, and NHL patients (NCT03465540)
AZD5991 AstraZeneca Ki  0.2 nM Phase I as a monotherapy in different R/R hematologic malignancies including
NHL, ALL, RS, SLL, T-cell lymphoma, CTCL, CLL, AML/MDS, and MM patients
(NCT03218683)
Phase II is sequential, dose-escalation study of combination AZD5991 plus
Venetoclax in R/R AML/MDS patients (NCT03218683)
VU661013 Stephen Fesik’s group at Vanderbilt
University
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In addition to pancreatic cancer cell line BxPC-3 xenograft mouse
model and MM animal xenografts, UMI-77 significantly delayed
growth activity in breast cancer cell line MDA-MB-468 xenograft
mouse model as well (Campbell and et al., 2018).
S63845
Developed in 2015 by a Servier and Vernalis partnership,
atropisomers thienopyrimidine scaffold molecule S63845 is a
selective BH3 mimetic Mcl-1 inhibitor that can activates the
Bax/Bak dependent mitochondrial apoptotic pathway (Kotschy
et al., 2016). S63845 is a selective and potent BH3 mimetic. It
binds with high affinity to the BH3-binding groove of Mcl-1 (Kd
 0.19 nM) without any detectable binding to Bcl-2 or Bcl-xL
proteins. S63845 showed effective anti-cancer activity in its
in vitro and in vivo preclinical studies (Kotschy et al., 2016).
The IV infusion of S63845 once daily for five consecutive days
resulted in 100% tumor regression in MM subcutaneous tumor
models and lymphoma disseminated mouse model Eμ-Myc
(Kotschy et al., 2016; Brennan et al., 2018). The same tumor
regression was related with AML as well (Kotschy et al., 2016).
This inhibitor had a therapeutic effect without significant weight
loss apparent side effects in normal mice tissues (Kotschy et al.,
2016). Along with A-1210477 and UMI-77, S63845 also inhibited
growth activity of TN breast cancer cell line (Campbell and et al.,
2018).
After S63845 proved its eligibility as a selective Mcl-1
antagonist, impressive studies have continued coming up.
Recently in 2019, S63845 showed activity both in vitro and in
vivo by killing human T cell acute lymphoblastic leukemia cells
(T-ALL) (Li et al., 2019). It was even more potent in inducing
apoptosis as a combination therapy with Venetoclax without any
appreciable toxicity (Li et al., 2019). In 2020, in vitro, ex vivo, and
in vivo preclinical evaluations investigated the combination of
S63845 plus Venetoclax. In vitro study tested the sensitivities of
five MM cell lines to the drug while the in vivo study used an
aggressive disseminated model of MM. The combined finding
came clearly with increasing apoptotic cell death, reduced cell
survival as well as delayed tumor growth in vivo (Algarín et al.,
2020). Furthermore, S63845 was evaluated in a triple
combination with Venetoclax plus dexamethasone. Clearly,
in vitro and in vivo studies showed that dexamethasone
increased the effectiveness of both S63845 and Venetoclax.
Furthermore, in vitro studies illustrated that the triple therapy
is a stronger synergism than the S63845 plus Venetoclax in
resistant MM cell line (MM.1S) (Algarín et al., 2020). In
addition, the combination of S63845 and Venetoclax,
enhanced the Venetoclax sensitivity and overcome resistance
to Venetoclax in human myeloma cell lines (HMCLs) (Wong
and Chim, 2020).
Servier and Vernalis and Novartis have created another
S-derivative called S64315 or MIK666. S64315/MIK666 is in
clinical trial as a single agent in R/R lymphoma or R/R MM
(NCT02992483). Furthermore, this molecule being tested in
AML and myelodysplastic syndrome (MDS) patients
(NCT02979366). Another clinical trial is undergoing by
Servier and Vernalis in a combination with Venetoclax in
AML patients (NCT03672695).
AMG-176
Developed in 2016 by Amgen, chirality macrocyclic
acylsulfonamide (spiromacrocyclic) AMG-176 is an orally
selective Mcl-1 inhibitor with high binding affinity (Ki 
0.06 nM), induces rapid apoptosis in different hematologic
malignancies. The treatment of AMG-176 disrupts the
interactions of the Mcl-1: Bak complex (Caenepeel et al., 2018;
Caenepeel and et al., 2017). Preclinical studies have demonstrated
that AMG-176 is non-toxic and efficacious in both MM
subcutaneous xenograft models and disseminated models,
inhibited 100% tumor growth (Caenepeel et al., 2018). In
preclinical studies, AMG-176 has been shown to eradicate CLL
cells as a single agent or in a combination with a low dose of
Venetoclax (Yi and et al., 2020). Interestingly, AMG-176 was the
first selective Mcl-1 inhibitor to be studied in humans. Currently,
AMG-176 is in phase I clinical trials via IV administrations in
patients with R/R MM and patients with R/R AML
(NCT02675452). AMG-176 monotherapy has potent anti-
myeloma and unique hematologic activity resulting in marked
survival improvement. Furthermore, phase I clinical trials have
also evaluated AMG-176 as a combination therapy with
Venetoclax which presents as an interesting therapy for
different R/R hematologic malignancies including AML,
diffuse large B cell lymphoma (DLBCL), and Non-Hodgkinʼs
lymphoma (NHL) (NCT03797261). Furthermore, as a
combination with MEK inhibitor (Trametinib), AMG-176
increased the tumor regression effect in murine models of
solid tumor cell lines (Nangia et al., 2018).
Amgen has developed another potent and selective analog
AM-8621, nonetheless, this molecule has poor oral bioavailability
and short half-life (Caenepeel et al., 2018). Interestingly, MM cells
showed sensitivity to AM-8621 as a monotherapy and as a
combination therapy with dexamethasone (Caenepeel et al.,
2018). Caenepeel et al. (2019) investigated the activities of
AMG 176 and AM-8621 in combination with Cytarabine,
Doxorubicin, and Decitabine in a preclinical models of AML
(Caenepeel and et al., 2019). The other analog AMG-397 is
evaluated orally in the clinic. A phase I clinical trial evaluating
its safety, tolerability, pharmacokinetics, and efficacy in MM,
AML, DLBCL, and NHL patients by administrating AMG-397 in
a weekly cycle consisting of two consecutive days of one oral dose
followed by five days off at a weekly interval (NCT03465540).
AZD5991
Developed in 2017 by AstraZeneca, indole-2-carboxylic acids
analog AZD5991, is a potent and selective macrocyclic Mcl-1
inhibitor that rapidly activates Caspase proteins, which leads to
apoptosis in MM cell lines (GI50  10 nM) (Hird and et al., 2017;
Tron et al., 2018). AZD5991 is a BH3 mimetic with high binding
affinity (Ki  0.2 nM) disrupts the Mcl-1: Bak complex (Hird and
et al., 2017; Tron et al., 2018). Most notably, in a number of MM
and AML mouse and rat xenograft models, AZD5991 exhibits a
potent activity with the preclinical in vivo studies showing 100%
tumor regression after a single IV dose in both monotherapy and
in combination with Venetoclax or Bortezomib (Tron et al.,
2018). The preclinical efficacy of AZD5991 is emphasized by
the apoptosis and survival improvements inMMmodels resistant
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to Venetoclax (Hird and et al., 2017). The remarkable in vitro and
in vivo anti-tumor activities of AZD5991 in both MM and AML
models support its consideration as a strong clinical candidate in
different Mcl-1 dependent hematologic malignancies. The
number of clinical trials are ongoing with AZD5991 as a
single agent or in combinations. For example, phase 1 as a
monotherapy dose escalation study in several R/R hematologic
malignancies including NHL, ALL, Richter syndrome (RS), small
lymphocytic lymphoma (SLL), T-cell lymphoma and cutaneous
T-cell lymphoma (CTCL) (NCT03218683); phase 1 as a
monotherapy in expansion groups of R/R CLL, AML/MDS,
and MM patients; and Phase 2 sequential, dose escalation
study in combination with Venetoclax in R/R AML/MDS
patients (NCT03218683).
VU661013
Developed in 2017 by Stephen Fesik’s group at Vanderbilt
University, indole-2-carboxylic acids analog VU661013 is a
potent and selective BH3 mimetic Mcl-1 inhibitor with high
binding affinity (Ki  0.097 nM) (Lee et al., 2017). VU661013
destabilizes the Mcl-1: Bim complex in order to initiate MOMP
(Ramsey et al., 2018). VU661013 proved potency in Mcl-1
inhibition in both in vitro and in vivo studies through its
induction of apoptosis in a variety of Mcl-1 dependent
tumors. Furthermore, it demonstrated efficacy in combination
with Venetoclax in Venetoclax resistant cells, patient derived
xenografts, andmurine models of AML (Ramsey et al., 2018). The
further modifications of this molecule is being made to improve
the efficacy and bioavailability. Another analog has been made
(compound 42), which bound to Mcl-1 with picomolar affinity
(Ki  70–300 pM) in order to displace Bim (Lee et al., 2019).
Compound 42 showed in vivo growth inhibition in xenograft
models of MM and AML (Lee et al., 2019).
CONCLUSION AND FUTURE DIRECTION
The anti-apoptotic protein Mcl-1 is critical in survival and drug
resistance of several malignancies including MM (Krajewska
et al., 1996; Miyamoto et al., 1999; Andersen et al., 2005; Song
et al., 2005; Ding et al., 2007; Boisvert-Adamo et al., 2009; Brotin
et al., 2010). Last decade or so has seen tremendous development,
various Mcl-1 inhibitors have been developed. These new
inhibitors may help in overcoming drug resistance and
improve treatment of MM and other hematological
malignancies where Mcl-1 is an important survival factor. The
numerous BH3 mimetic and semi BH3 mimetic drugs have
proved their efficacy in preclinical studies. Hopefully, after
clinical trial of one of these numerous drugs receive FDA
approval. It may open up a new door in the targeted MM
therapy that will help to improve medical approaches, and the
outcome of MM patients. Although, Mcl-1 inhibitors have good
anti-myeloma activity as a monotherapy in hematological cancer
models, most development strategies are focused on
combination, which can increase the potential of these
molecules. These combinations are shown to be especially
valuable if the drug consists of a selective Mcl-1 inhibitor plus
an existing drug that inhibits other anti-apoptotic proteins
including Bcl-2 and Bcl-xL, and/or drug that induce pro-
apoptotic proteins expression. Combination therapies such as
selective Bcl-2 proteins inhibitors or proteasome inhibitors
(Venetoclax or Bortezomib) have been attempted to improve
the therapeutic outcome (Caenepeel et al., 2018; Ramsey et al.,
2018; Tron et al., 2018; Moujalled et al., 2019). Furthermore, the
triple combination therapy plus dexamethasone has shown a
good effect and presents as an effective strategy (Algarín et al.,
2020). Interestingly, three of the recently developed BH3-mimetic
are in clinical trials as a combination therapy with Venetoclax.
These combination strategies allow patients to interrupt
treatment for long periods of time and show a successful
development for this new drug class. Based on this
information, nowadays the small molecule BH3 mimetics and
semi mimetics compounds represent the most promising
approach for the selective inhibition of Mcl-1. This places the
priority on the rational design of novel BH3 mimetic drugs that
binds extremely tightly and selectively to Mcl-1 for the better
outcome of the treatment.
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